SPY416.07+3.90 0.95%
DIA341.30+3.18 0.94%
IXIC13,950.22+163.95 1.19%

Codiak BioSciences: First Human Proof-Of-Concept Data From exoIL-12 Program Confirmed Desired Pdt Profile and Enabled Dose Selection for Further Evaluation in Patients >CDAK

Codiak BioSciences: First Human Proof-Of-Concept Data From exoIL-12 Program Confirmed Desired Pdt Profile and Enabled Dose Selection for Further Evaluation in Patients >CDAK

· 03/17/2021 07:37

Please log in to view news